SLC5A2 and chronic kidney disease: However, results of CREDENCE and DAPA-CKD trial indicated that SGLT2 inhibitors could reduce the risk of renal events with no restrictions of baseline eGFR and thus were recommended for T2DM patients with DKD and eGFR ≥ 30 ml/min/1.73 m28–10,17.